Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort

Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothened Inhibition

(2014) Marcel Kool et al.   CANCER CELL

DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies

(2013) Edward C. Schwalbe et al.   ACTA NEUROPATHOLOGICA

Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays

(2013) Volker Hovestadt et al.   ACTA NEUROPATHOLOGICA

Subgroup-Specific Prognostic Implications ofTP53Mutation in Medulloblastoma

(2013) Nataliya Zhukova et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas

(2012) Marcel Kool et al.   ACTA NEUROPATHOLOGICA

Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53 Mutations

(2012) Tobias Rausch et al.   CELL

Outcome of Children With Metastatic Medulloblastoma Treated With Carboplatin During Craniospinal Radiotherapy: A Children's Oncology Group Phase I/II Study

(2012) Regina I. Jakacki et al.   JOURNAL OF CLINICAL ONCOLOGY

Dissecting the genomic complexity underlying medulloblastoma

(2012) David T. W. Jones et al.   NATURE

Molecular subgroups of medulloblastoma: the current consensus

(2011) Michael D. Taylor et al.   ACTA NEUROPATHOLOGICA

Adult Medulloblastoma Comprises Three Major Molecular Variants

(2011) Marc Remke et al.   JOURNAL OF CLINICAL ONCOLOGY

Adult and Pediatric Medulloblastomas Are Genetically Distinct and Require Different Algorithms for Molecular Risk Stratification

(2010) Andrey Korshunov et al.   JOURNAL OF CLINICAL ONCOLOGY

TP53 Mutation Is Frequently Associated With CTNNB1 Mutation or MYCN Amplification and Is Compatible With Long-Term Survival in Medulloblastoma

(2010) Elke Pfaff et al.   JOURNAL OF CLINICAL ONCOLOGY

Integrative Genomic Analysis of Medulloblastoma Identifies a Molecular Subgroup That Drives Poor Clinical Outcome

(2010) Yoon-Jae Cho et al.   JOURNAL OF CLINICAL ONCOLOGY

Medulloblastoma Comprises Four Distinct Molecular Variants

(2010) Paul A. Northcott et al.   JOURNAL OF CLINICAL ONCOLOGY

Medulloblastoma Variants: Age-Dependent Occurrence and Relation to Gorlin Syndrome--A New Clinical Perspective

(2009) M. L. Garre et al.   CLINICAL CANCER RESEARCH

Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT‘91

(2009) Katja von Hoff et al.   EUROPEAN JOURNAL OF CANCER

Outcome Prediction in Pediatric Medulloblastoma Based on DNA Copy-Number Aberrations of Chromosomes 6q and 17q and theMYCandMYCNLoci

(2009) Stefan Pfister et al.   JOURNAL OF CLINICAL ONCOLOGY

Integrated Genomics Identifies Five Medulloblastoma Subtypes with Distinct Genetic Profiles, Pathway Signatures and Clinicopathological Features

(2008) Marcel Kool et al.   PLoS One